Completed PHASE2 INTERVENTIONAL NCT00119457

Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis With Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Following Hip Fracture Surgery

Sponsor: vTv Therapeutics

Conditions Embolism and Thrombosis Hip Fractures Venous Thromboembolism

Interventions TTP889

Updated 7 times since 2017 Last updated: Jun 2, 2009 Started: Jan 31, 2005 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Embolism and Thrombosis and Hip Fractures and is currently completed. vTv Therapeutics leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

vTv Therapeutics

Data source: vTv Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Copenhagen, Denmark , Farsø, Denmark , Gjøvik, Norway , Gothenburg, Sweden , Hellerup, Denmark , Herlev, Denmark , Hørsholm, Denmark , Kungälv, Sweden , Lillehammer, Norway and 10 more locations